Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
Depending on the type of cancer, it can be used as monotherapy or combination as a part of first line regimen, maintenance regimen or relapsed settings
Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
Subscribe To Our Newsletter & Stay Updated
